To maximize the clinical benefits of targeted‐therapy and immunotherapy, several studies have investigated concurrent combinations of MAPK inhibitors and ICIs in patients with advanced melanoma [508]; and some of them have examined the combinations of BRAF and MEK inhibitors with PD‐1/PD‐L1 inhibitors in patients with BRAFmut melanoma [21, 22, 24, 509, 510, 511]. The gene discussed is PDCD1; the disease is melanoma.